Changes to the restriction on the supply of Sativex

On 1 April 2020 the current restriction on the supply of Sativex^TM has changed following a Notice published in the New Zealand Gazette 4 March 2020.

Sativex^TM is a cannabis-based product that is classified as a controlled drug. While Sativex^TM was consented as a medicine from 19 November 2010 as Sativex Oral Spray, case-by-case approval from the Minister of Health has been required for all new prescriptions for off-label use of Sativex.

From 1 April 2020, registered medical practitioners no longer need Ministerial approval to prescribe Sativex^TM for off-label use for patients under their care, where this is within their scope of practice.

When a prescription has been issued, Sativex^TM can be dispensed to the patient by a registered pharmacist, or by a registered medical practitioner if the patient is in their care.

For further information, please see the Gazette Notice.

The changes to the availability of Sativex^TM coincide with the commencement of the Medicinal Cannabis Scheme, which will increase the range of quality medicinal cannabis products available for patients over time. Information about the scheme, including guidance for health practitioners, is available on the Ministry of Health website.